サンプル依頼リスト カート
  • English
  • Korean
デフォルト表紙
市場調査レポート
商品コード
1386284

ヒトパピローマウイルス（HPV）ワクチン市場レポート：2030年までの動向、予測、競合分析

Human Papillomavirus (HPV) Vaccine Market Report: Trends, Forecast and Competitive Analysis to 2030
出版日: | 発行: Lucintel | ページ情報: 英文 150 Pages | 納期: 3営業日

● お客様のご希望に応じて、既存データの加工や未掲載情報（例：国別セグメント）の追加などの対応が可能です。　 詳細はお問い合わせください。

価格
価格表記: USDを日本円(税抜)に換算
本日の銀行送金レート: 1USD=155.11円

ご注意:　DRM (デジタル著作権管理システム) 付PDFになります。
制限内容は、上記ライセンスの[詳細]アイコンをクリックしてご確認ください。

ヒトパピローマウイルス（HPV）ワクチン市場レポート：2030年までの動向、予測、競合分析
出版日: 2023年10月03日
発行: Lucintel
ページ情報: 英文 150 Pages
納期: 3営業日
ご注意事項 :
本レポートは最新情報反映のため適宜更新し、内容構成変更を行う場合があります。ご検討の際はお問い合わせください。
  • 全表示
  • 概要
  • 目次
概要

ヒトパピローマウイルス（HPV）ワクチンの動向と予測

ヒトパピローマウイルス（HPV）ワクチンの世界市場は、2024年から2030年までのCAGRが10.4%で、2030年までに推定103億米ドルに達すると予測されます。この市場の主な促進要因は、HPVワクチン接種の利点に対する認識の高まり、HPV感染症の有病率の上昇、HPVワクチン接種を推進する政府のイニシアチブの高まりです。ヒトパピローマウイルス（HPV）ワクチンの世界市場の将来性は、病院・小売薬局および政府供給チャネルにおけるビジネスチャンスにより有望視されています。

ヒトパピローマウイルス（HPV）ワクチン市場洞察

Lucintelの予測では、4価ワクチンは安全性と有効性といった特徴から、9～12歳の女児と男児に広く使用されているため、予測期間中に最も高い成長が見込まれます。

北米は、HPVワクチンの採用率が高く、HPVワクチン接種を促進する政府の取り組みが増加していることから、予測期間中に最も高い成長が見込まれます。

本レポートでは、以下の11の主要な質問に回答している：

  • Q.1.市場セグメントのうち、最も有望かつ高成長な機会は何か？
  • Q.2.どのセグメントがより速いペースで成長するのか、またその理由は？
  • Q.3.今後成長が加速すると思われる地域とその理由は？
  • Q.4.市場力学に影響を与える主な要因は何か？市場における主な課題とビジネスリスクは？
  • Q.5.この市場におけるビジネスリスクと競合の脅威は？
  • Q.6.この市場における新たな動向とその理由は？
  • Q.7.市場における顧客の需要の変化にはどのようなものがありますか？
  • Q.8.この市場における新たな開発と、その開発をリードしている企業は？
  • Q.9.この市場における主要企業は？主要企業は事業成長のためにどのような戦略的取り組みを進めているのか？
  • Q.10.この市場における競合製品にはどのようなものがあり、材料や製品の代替による市場シェア低下の脅威はどの程度ありますか？
  • Q.11.過去5年間にどのようなM&Aが行われ、業界にどのような影響を与えましたか？

目次

第1章 エグゼクティブサマリー

第2章 世界のヒトパピローマウイルス（HPV）ワクチン市場：市場力学

  • イントロダクション、背景、分類
  • サプライチェーン
  • 業界の促進要因と課題

第3章 2018年から2030年までの市場動向と予測分析

  • マクロ経済動向（2018～2023年）と予測（2024～2030年）
  • 世界のヒトパピローマウイルス（HPV）ワクチン市場動向（2018～2023年）と予測（2024～2030年）
  • タイプ別の世界のヒトパピローマウイルス（HPV）ワクチン市場
    • 四価
    • 九価
    • 二価
  • 流通チャネル別の世界のヒトパピローマウイルス（HPV）ワクチン市場
    • 病院および小売薬局
    • 政府のサプライヤー
    • その他

第4章 2018年から2030年までの地域別の市場動向と予測分析

  • 地域別の世界のヒトパピローマウイルス（HPV）ワクチン市場
  • 北米のヒトパピローマウイルス（HPV）ワクチン市場
  • 欧州のヒトパピローマウイルス（HPV）ワクチン市場
  • アジア太平洋ヒトパピローマウイルス（HPV）ワクチン市場
  • その他地域ヒトパピローマウイルス（HPV）ワクチン市場

第5章 競合の分析

  • 製品ポートフォリオ分析
  • 運用上の統合
  • ポーターのファイブフォース分析

第6章 成長機会と戦略的分析

  • 成長機会分析
    • タイプ別の世界のヒトパピローマウイルス（HPV）ワクチン市場の成長機会
    • 流通チャネル別の世界のヒトパピローマウイルス（HPV）ワクチン市場の成長機会
    • 地域別の世界のヒトパピローマウイルス（HPV）ワクチン市場の成長機会
  • 世界のヒトパピローマウイルス（HPV）ワクチン市場の新たな動向
  • 戦略的分析
    • 新製品の開発
    • 世界のヒトパピローマウイルス（HPV）ワクチン市場の生産能力拡大
    • 世界のヒトパピローマウイルス（HPV）ワクチン市場における合併、買収、合弁事業
    • 認証とライセンシング

第7章 有力企業の企業プロファイル

  • Johnson & Johnson
  • Xenetic Biosciences
  • AstraZeneca
  • Merck
  • Serum Institute of India
  • Inovio Pharmaceuticals
  • Bharat Biotech
  • Sanofi
  • GlaxoSmithKline
  • Novartis
目次

Human Papillomavirus (HPV) Vaccine Trends and Forecast

The future of the global human papillomavirus (HPV) vaccine market looks promising with opportunities in the hospital & retail pharmacy and government supplier channels. The global human papillomavirus (HPV) vaccine market is expected to reach an estimated $10.3 billion by 2030 with a CAGR of 10.4% from 2024 to 2030. The major drivers for this market are increasing awareness of the benefits of HPV vaccination, rising prevalence of HPV infection, and rising government initiatives to promote HPV vaccination.

A more than 150-page report is developed to help in your business decisions.

Human Papillomavirus (HPV) Vaccine by Segment

The study includes a forecast for the global human papillomavirus (HPV) vaccine by type, distribution channel, and region.

Human Papillomavirus (HPV) Vaccine Market by Type [Shipment Analysis by Value from 2018 to 2030]:

  • Tetravalent
  • Nonavalent
  • Bivalent

Human Papillomavirus (HPV) Vaccine Market by Distribution Channel [Shipment Analysis by Value from 2018 to 2030]:

  • Hospital & Retail Pharmacies
  • Government Suppliers
  • Others

Human Papillomavirus (HPV) Vaccine Market by Region [Shipment Analysis by Value from 2018 to 2030]:

  • North America
  • Europe
  • Asia Pacific
  • The Rest of the World

List of Human Papillomavirus (HPV) Vaccine Companies

Companies in the market compete on the basis of product quality offered. Major players in this market focus on expanding their manufacturing facilities, R&D investments, infrastructural development, and leverage integration opportunities across the value chain. With these strategies human papillomavirus (HPV) vaccine companies cater increasing demand, ensure competitive effectiveness, develop innovative products & technologies, reduce production costs, and expand their customer base. Some of the human papillomavirus (HPV) vaccine companies profiled in this report include-

  • Johnson & Johnson
  • Xenetic Biosciences
  • AstraZeneca
  • Merck
  • Serum Institute Of India
  • Inovio Pharmaceuticals
  • Bharat Biotech
  • Sanofi
  • GlaxoSmithKline
  • Novartis

Human Papillomavirus (HPV) Vaccine Market Insights

Lucintel forecasts that tetravalent is expected to witness highest growth over the forecast period due to its significant usage among girls and boys ages 9 through 12 owing to its features like safety and effectiveness.

North America is expected to witness highest growth over the forecast perioddue to higher adopotion of HPV vaccine and increasing government initiatives to promote HPV vaccination in the region.

Features of the Global Human Papillomavirus (HPV) Vaccine Market

Market Size Estimates: Human papillomavirus (HPV) vaccine market size estimation in terms of value ($B).

Trend and Forecast Analysis: Market trends (2018 to 2023) and forecast (2024 to 2030) by various segments and regions.

Segmentation Analysis: Human papillomavirus (HPV) vaccine market size by type, distribution channel, and region in terms of value ($B).

Regional Analysis: Human papillomavirus (HPV) vaccine market breakdown by North America, Europe, Asia Pacific, and Rest of the World.

Growth Opportunities: Analysis of growth opportunities in different types, distribution channels, and regions for the human papillomavirus (HPV) vaccine market.

Strategic Analysis: This includes M&A, new product development, and competitive landscape of the human papillomavirus (HPV) vaccine market.

Analysis of competitive intensity of the industry based on Porter's Five Forces model.

FAQ

Q.1 What is the human papillomavirus (HPV) vaccine market size?

Answer: The global human papillomavirus (HPV) vaccine market is expected to reach an estimated $10.3 billion by 2030.

Q.2 What is the growth forecast for human papillomavirus (HPV) vaccine market?

Answer: The global human papillomavirus (HPV) vaccine market is expected to grow with a CAGR of 10.4% from 2024 to 2030.

Q.3 What are the major drivers influencing the growth of the human papillomavirus (HPV) vaccine market?

Answer: The major drivers for this market are increasing awareness of the benefits of HPV vaccination, rising prevalence of HPV infection, and rising government initiatives to promote HPV vaccination.

Q4. What are the major segments for human papillomavirus (HPV) vaccine market?

Answer: The future of the human papillomavirus (HPV) vaccine market looks promising with opportunities in the hospital & retail pharmacy and government supplier channels.

Q5. Who are the key human papillomavirus (HPV) vaccine market companies?

Answer: Some of the key human papillomavirus (HPV) vaccine companies are as follows:

  • Johnson & Johnson
  • Xenetic Biosciences
  • AstraZeneca
  • Merck
  • Serum Institute Of India
  • Inovio Pharmaceuticals
  • Bharat Biotech
  • Sanofi
  • GlaxoSmithKline
  • Novartis

Q6. Which human papillomavirus (HPV) vaccine market segment will be the largest in future?

Answer: Lucintel forecasts that tetravalent is expected to witness highest growth over the forecast period due to its significant usage among girls and boys ages 9 through 12 owing to its features like safety and effectiveness.

Q7. In human papillomavirus (HPV) vaccine market, which region is expected to be the largest in next 5 years?

Answer: North America is expected to witness highest growth over the forecast perioddue to higher adopotion of HPV vaccine and increasing government initiatives to promote HPV vaccination in the region.

Q.8 Do we receive customization in this report?

Answer: Yes, Lucintel provides 10% customization without any additional cost.

This report answers following 11 key questions:

  • Q.1. What are some of the most promising, high-growth opportunities for the human papillomavirus (HPV) vaccine market by type (tetravalent, nonavalent, and bivalent), distribution channel (hospital & retail pharmacies, government suppliers, and others), and region (North America, Europe, Asia Pacific, and the Rest of the World)?
  • Q.2. Which segments will grow at a faster pace and why?
  • Q.3. Which region will grow at a faster pace and why?
  • Q.4. What are the key factors affecting market dynamics? What are the key challenges and business risks in this market?
  • Q.5. What are the business risks and competitive threats in this market?
  • Q.6. What are the emerging trends in this market and the reasons behind them?
  • Q.7. What are some of the changing demands of customers in the market?
  • Q.8. What are the new developments in the market? Which companies are leading these developments?
  • Q.9. Who are the major players in this market? What strategic initiatives are key players pursuing for business growth?
  • Q.10. What are some of the competing products in this market and how big of a threat do they pose for loss of market share by material or product substitution?
  • Q.11. What M&A activity has occurred in the last 5 years and what has its impact been on the industry?

Table of Contents

1. Executive Summary

2. Global Human Papillomavirus (HPV) Vaccine Market : Market Dynamics

  • 2.1: Introduction, Background, and Classifications
  • 2.2: Supply Chain
  • 2.3: Industry Drivers and Challenges

3. Market Trends and Forecast Analysis from 2018 to 2030

  • 3.1. Macroeconomic Trends (2018-2023) and Forecast (2024-2030)
  • 3.2. Global Human Papillomavirus (HPV) Vaccine Market Trends (2018-2023) and Forecast (2024-2030)
  • 3.3: Global Human Papillomavirus (HPV) Vaccine Market by Type
    • 3.3.1: Tetravalent
    • 3.3.2: Nonavalent
    • 3.3.3: Bivalent
  • 3.4: Global Human Papillomavirus (HPV) Vaccine Market by Distribution Channel
    • 3.4.1: Hospital & Retail Pharmacies
    • 3.4.2: Government Suppliers
    • 3.4.3: Others

4. Market Trends and Forecast Analysis by Region from 2018 to 2030

  • 4.1: Global Human Papillomavirus (HPV) Vaccine Market by Region
  • 4.2: North American Human Papillomavirus (HPV) Vaccine Market
    • 4.2.2: North American Human Papillomavirus (HPV) Vaccine Market by Distribution Channel: Hospital & Retail Pharmacies, Government Suppliers, and Others
  • 4.3: European Human Papillomavirus (HPV) Vaccine Market
    • 4.3.1: European Human Papillomavirus (HPV) Vaccine Market by Type: Tetravalent, Nonavalent, and Bivalent
    • 4.3.2: European Human Papillomavirus (HPV) Vaccine Market by Distribution Channel: Hospital & Retail Pharmacies, Government Suppliers, and Others
  • 4.4: APAC Human Papillomavirus (HPV) Vaccine Market
    • 4.4.1: APAC Human Papillomavirus (HPV) Vaccine Market by Type: Tetravalent, Nonavalent, and Bivalent
    • 4.4.2: APAC Human Papillomavirus (HPV) Vaccine Market by Distribution Channel: Hospital & Retail Pharmacies, Government Suppliers, and Others
  • 4.5: ROW Human Papillomavirus (HPV) Vaccine Market
    • 4.5.1: ROW Human Papillomavirus (HPV) Vaccine Market by Type: Tetravalent, Nonavalent, and Bivalent
    • 4.5.2: ROW Human Papillomavirus (HPV) Vaccine Market by Distribution Channel: Hospital & Retail Pharmacies, Government Suppliers, and Others

5. Competitor Analysis

  • 5.1: Product Portfolio Analysis
  • 5.2: Operational Integration
  • 5.3: Porter's Five Forces Analysis

6. Growth Opportunities and Strategic Analysis

  • 6.1: Growth Opportunity Analysis
    • 6.1.1: Growth Opportunities for the Global Human Papillomavirus (HPV) Vaccine Market by Type
    • 6.1.2: Growth Opportunities for the Global Human Papillomavirus (HPV) Vaccine Market by Distribution Channel
    • 6.1.3: Growth Opportunities for the Global Human Papillomavirus (HPV) Vaccine Market by Region
  • 6.2: Emerging Trends in the Global Human Papillomavirus (HPV) Vaccine Market
  • 6.3: Strategic Analysis
    • 6.3.1: New Product Development
    • 6.3.2: Capacity Expansion of the Global Human Papillomavirus (HPV) Vaccine Market
    • 6.3.3: Mergers, Acquisitions, and Joint Ventures in the Global Human Papillomavirus (HPV) Vaccine Market
    • 6.3.4: Certification and Licensing

7. Company Profiles of Leading Players

  • 7.1: Johnson & Johnson
  • 7.2: Xenetic Biosciences
  • 7.3: AstraZeneca
  • 7.4: Merck
  • 7.5: Serum Institute of India
  • 7.6: Inovio Pharmaceuticals
  • 7.7: Bharat Biotech
  • 7.8: Sanofi
  • 7.9: GlaxoSmithKline
  • 7.10: Novartis